Drug Delivery Devices Market is predicted to reach USD ~387.0 Billion at a CAGR of 4.90% during the forecast period 2023 to 2032.

Market Research Future (MRFR) has published a cooked research report on the “Global Drug Delivery Devices Market” that contains information from 2018 to 2032. The drug delivery devices market is estimated to register a CAGR of 4.90% during the forecast period of 2023 to 2032.

MRFR recognizes the following companies as the key players in the global drug delivery devices market— Pfizer, Inc., F. Hoffmann-La Roche Ltd, Johnson and Johnson Private Ltd, Novartis AG, Bayer AG, Becton, Dickinson and Company, and Uniqure NV

Market Highlights

The global drug delivery devices market is accounted to register a CAGR of 4.90% during the forecast period and is estimated to reach USD 387.0 Billion by 2032.

The market for drug delivery devices includes all businesses that manufacture and sell equipment used to give patients their drugs. The rising frequency of chronic diseases, the necessity for convenient and precise drug administration, and developments in healthcare technology are all driving forces in this industry. It provides a variety of cutting-edge tools, like inhalers, injectors, and patches, to improve patient care and therapeutic results.

Segment Analysis

The global drug delivery devices market has been segmented based route of administration, application and end user.

On the basis of route of administration, the market is segmented into oral, ocular, inhalation, nasal, injectable, topical, and others. Oral segment dominated the global market in 2022. For the oral drug delivery method, a variety of dose forms are available, including tablets, capsules, syrups, solutions, and suspensions.

Based on application, the global drug delivery devices market has been segmented into cardiovascular, diabetes, cancer, infectious diseases, and others. Diabetes segment dominated the global market in 2022. The prevalence of diabetes is on the rise, which is the main contributor. For instance, according to the American Diabetes Association (ADA), 34.2 million Americans had diabetes in 2018, of which 26.8 million had received a diagnosis and 7.3 million had not.

Based on end user, the global drug delivery devices market has been segmented into hospitals, ambulatory services, and home healthcare. Hospitals segment dominated the global drug delivery devices market in 2022. To treat the variety of ailments that hospitalized patients present with, several drugs and drug delivery techniques are used.

Browse In-depth Market Details [Table of Content, List of Figures, List of Tables] of Drug Delivery Devices Market Research Report

Regional Analysis

The global drug delivery devices market, based on region, has been divided into the North America, Europe, Asia-Pacific, and Rest of the World. North America consists of US and Canada. The Europe Drug Delivery Devices market comprises of Germany, France, the UK, Italy, Spain, and the rest of Europe. The Drug Delivery Devices market in Asia-Pacific has been segmented into China, India, Japan, Australia, South Korea, and the rest of Asia-Pacific. The Rest of the World Drug Delivery Devices market comprises of Middle East, Africa, and Latin America.

The North America drug delivery devices market dominated this market in 2022 (45.80%). This is a result of the area's presence of major players and the growing use of drug delivery methods. Additionally, it is projected that growing local awareness of the advantages of medication delivery devices will encourage market expansion in the region. Additionally, it is projected that increased product approval in countries like the US will assist market expansion. The nasal medicine delivery device from Aptar Pharma received U.S. FDA approval in March 2019.

Moreover, in 2022, Europe's market for drug delivery devices held a sizable market share. Top market players in the region have a ton of opportunities, in part because of mature economies and alluring regulatory frameworks.

Additionally, from 2023 to 2032, the Asia Pacific drug delivery devices market is anticipated to grow significantly. This is a result of the region's quick economic growth. A large patient population is also driving a range of end users to employ pharmaceutical delivery systems in countries like China, India, and Japan. Furthermore, several drug delivery methods are employed in Japan to give specific types of drugs.

Furthermore, the rest of the world's drug delivery devices market is divided into the Middle East, Africa, and Latin America. The market for devices used in the delivery of drugs in Latin America satisfies regional demand. In order to enhance patient care and treatment outcomes in Latin American nations, the market now offers a number of cutting-edge drug delivery devices, such as inhalers, injectors, and patches, in response to growing healthcare developments and the prevalence of chronic diseases.

Key Findings of the Study

• The global drug delivery devices market is expected to reach USD 387.0 Billion by 2032, at a CAGR of 4.90% during the forecast period.


• The Asia-Pacific region accounted for the fastest-growing global market due to the area's rapid economic expansion.


• Based on end user, the hospitals segment was attributed to holding the largest market in 2022.


• Pfizer, Inc., F. Hoffmann-La Roche Ltd, Johnson and Johnson Private Ltd, Novartis AG, Bayer AG, Becton, Dickinson and Company, and Uniqure NV.